<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mills, Anthony</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">No Resistance and Improved Renal and Bone Profiles with a Single-Table Regimen of D/C/F/TAF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-22</style></pages><abstract><style  face="normal" font="default" size="100%">Darunavir is a protease inhibitor (PI) dosed as a single daily tablet. PIs have a high genetic barrier to resistance, but a PI-based single-tablet regimen has not been available. This article presents the results of the week 48 analysis of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-Boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naïve Adults [GS-US-299-0102; NCT01565850].</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>